pharma & biotech2020-06-10
The FDA has approved nivolumab for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma. Source: OncLive....Read more
pharma & biotech2020-06-10
Adding pembrolizumab to chemotherapy did not lead to a statistically significant improvement in overall survival or progression-free survival in patients with advanced or metastatic urothelial carcinoma, according to findings from the phase 3 KEYNOTE-361 trial. Source: OncLive....Read more
pharma & biotech2020-06-10
Rana R. McKay, MD, discusses the design and key findings of the OMNIVORE trial, as well as other ongoing adaptive trials in renal cell carcinoma. Source: OncLive....Read more
pharma & biotech2020-06-10
Naveen Pemmaraju, MD, discusses the potential benefit of rechallenging ruxolitinib in patients with myelofibrosis. Source: OncLive....Read more
pharma & biotech2020-06-10
The combination of nivolumab plus ipilimumab was found to induce a superior response rate and longer progression-free survival compared with nivolumab alone in patients with persistent or recurrent epithelial ovarian cancer. Source: OncLive....Read more
pharma & biotech2020-06-10
The 4-drug ABCP regimen improved survival while maintaining good health-related quality of life in patients with nonsquamous non–small cell lung cancer, according to patient-reported outcomes from the phase 3 IMpower150 trial. Source: OncLive....Read more
pharma & biotech2020-06-10
The novel HER2-directed antibody-drug conjugate trastuzumab deruxtecan-nxki demonstrated promising antitumor activity in patients with heavily pretreated, HER2 low-expressing advanced or metastatic breast cancer. Source: OncLive....Read more
pharma & biotech2020-06-09
Richard R. Furman, MD, discusses the findings from the analysis and highlights the differences between first- and second-generation BTK inhibitors in CLL. Source: OncLive....Read more
pharma & biotech2020-06-09
Salvatore Siena, MD, further discusses the DESTINY-CRC01 trial with trastuzumab deruxtecan and projects the impact of these findings on patients with HER2-expressing metastatic CRC. Source: OncLive....Read more
pharma & biotech2020-06-09
Philip A. Philip, MD, PhD, FRCP, discusses challenges in pancreatic cancer and the emergence of devimistat in the treatment paradigm. Source: OncLive....Read more
Load More
